Technical Analysis for IRWD - Ironwood Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
D 10.21 0.99% 0.10
IRWD closed up 0.99 percent on Monday, March 8, 2021, on 2.25 times normal volume. It ran into resistance at its 50 day moving average. Its advance stalled at its 200 day moving average, an important long-term support / resistance line.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Up
Historical IRWD trend table...

Date Alert Name Type % Chg
200 DMA Resistance Bearish 0.00%
50 DMA Resistance Bearish 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
Up 3 Days in a Row Strength 0.00%
Up 4 Days in a Row Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.99%
Pocket Pivot Bullish Swing Setup 0.99%
NR7 Range Contraction 0.99%
Older End-of-Day Signals for IRWD ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Gap Up Partially Closed about 8 hours ago
60 Minute Opening Range Breakdown about 8 hours ago
200 DMA Resistance about 8 hours ago
Possible Pocket Pivot about 9 hours ago
Rose Above Upper Bollinger Band about 12 hours ago
View Earlier Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Ironwood Pharmaceuticals, Inc. Description

Ironwood Pharmaceuticals, Inc., an entrepreneurial pharmaceutical company, discovers, develops, and commercializes human therapeutic products. The company's lead product candidate, linaclotide, a guanylate cyclase type-C agonist for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) gastrointestinal disorders under the LINZESS name in the United States and Constella name in the European Union. It also has a pipeline focused on the research and development of early development candidates and discovery research programs in various therapeutic areas, including gastrointestinal diseases, central nervous system disorders, allergic conditions, and cardiovascular diseases. Ironwood Pharmaceuticals has collaboration and license agreements with Forest Laboratories, Inc. to develop and commercialize linaclotide in North America; Almirall, S.A to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other gastrointestinal conditions; Astellas Pharma Inc. to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other gastrointestinal conditions in Japan, South Korea, Taiwan, Thailand, the Philippines, and Indonesia; and AstraZeneca AB to co-develop and co-commercialize linaclotide in China, including Hong Kong and Macau. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was founded in 1998 and is headquartered in Cambridge, Massachusetts.


Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Gastrointestinal Therapeutic Product Cardiovascular Disease Therapeutic Products Nervous System Disorders Central Nervous System Disorders Gastroenterology Peptides Vascular Diseases Cardiovascular Diseases Macau Gastrointestinal Disease Gastrointestinal Diseases European Union Irritable Bowel Syndrome Constipation Digestive Diseases Gastrointestinal Disorders Laxatives Human Therapeutic Products Linaclotide

Is IRWD a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 12.55
52 Week Low 7.99
Average Volume 1,792,256
200-Day Moving Average 10.38
50-Day Moving Average 10.51
20-Day Moving Average 9.80
10-Day Moving Average 9.65
Average True Range 0.47
ADX 20.79
+DI 27.34
-DI 16.29
Chandelier Exit (Long, 3 ATRs ) 9.97
Chandelier Exit (Short, 3 ATRs ) 10.21
Upper Bollinger Band 10.67
Lower Bollinger Band 8.92
Percent B (%b) 0.74
BandWidth 17.83
MACD Line -0.16
MACD Signal Line -0.29
MACD Histogram 0.1308
Fundamentals Value
Market Cap 1.63 Billion
Num Shares 160 Million
EPS 0.70
Price-to-Earnings (P/E) Ratio 14.61
Price-to-Sales 4.60
Price-to-Book 314.01
PEG Ratio -0.26
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 11.04
Resistance 3 (R3) 11.12 10.91 10.90
Resistance 2 (R2) 10.91 10.70 10.88 10.86
Resistance 1 (R1) 10.56 10.57 10.46 10.49 10.81
Pivot Point 10.36 10.36 10.31 10.32 10.36
Support 1 (S1) 10.01 10.15 9.91 9.93 9.61
Support 2 (S2) 9.80 10.02 9.77 9.56
Support 3 (S3) 9.45 9.80 9.52
Support 4 (S4) 9.38